Inflammatory mediators are predictors of clinical outcomes in cirrhotic patients with non-acute decompensation.
Elevated IL-10 and IL-6 levels in patients with non-acute decompensation are associated with a significantly increased risk of severe liver-related outcomes, but further research is needed to confirm these findings.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpusSummary and findings
This study evaluated the prognostic value of inflammatory mediators in patients with non-acute decompensation (NAD). It included 373 patients in a retrospective cohort and 192 patients in a prospective cohort, with a follow-up duration of 24 months. The study found that elevated levels of IL-10 and IL-6 independently predicted adverse clinical outcomes.
Abstract
<h4>Background</h4>Non-acute decompensation (NAD) has been proposed as a distinct pathway of decompensation. This study evaluated the prognostic value of inflammatory mediators for subsequent clinical outcomes in patients with NAD.<h4>Methods</h4>Outpatients with NAD were included in this ambispective cohort study (Cohort 1 retrospectively; Cohort 2: prospectively). Patients were followed for 24 months. The primary endpoints were the occurrence of acute decompensation (AD), acute-on-chronic liver failure (ACLF), and liver-transplantation-free mortality.<h4>Results</h4>Cohort 1 ultimately comprised 373 patients. Cohort 2 included 192 patients. In multivariable analysis of cohort 1, both IL-10 and IL-6 levels independently predicted AD (log-transformed-IL-10, HR: 1.26; 95% confidence interval, CI: 1.16-1.36; P < 0.001; log-transformed-IL-6, HR: 1.13; 95% CI: 1.01-1.27; P = 0.03) and ACLF (log-transformed-IL-10, HR: 2.03; 95% CI: 1.57-2.64; P < 0.001; log-transformed-IL-6, HR: 2.21; 95% CI: 1.57-3.11; P < 0.001). Patients were stratified into three groups: no systemic inflammation (SI), SI without immunodeficiency (ID), and SI with ID (elevated IL-6 + IL-10). While SI alone increased AD risk, the coexistence of ID markedly amplified the risk of severe outcomes. Compared to SI alone, patients with SI + ID had a substantially higher risk of ACLF (Cohort 1 (training) HR: 28.02; 95% CI: 12.54-62.62; Cohort 2 (validating) HR: 39.78; 95% CI: 10.97-144.30). Nearly all deaths occurred in the SI + ID subgroup [Cohort 1: 10/10; Cohort 2: 4/5].<h4>Conclusions</h4>A combined biomarker profile of SI (IL-6) and ID (IL-10) identifies a distinct high-risk subgroup among NAD outpatients, characterized by a markedly elevated risk of progression to AD, ACLF and liver-transplantation-free mortality.
Background
The paper addresses the role of inflammatory mediators as potential predictors of clinical outcomes in cirrhotic patients experiencing non-acute decompensation. Prior research has suggested that inflammation may play a significant role in the progression of liver disease, but specific mediators and their impact on clinical outcomes have not been thoroughly examined. This study aims to fill that gap by analyzing the relationship between these mediators and patient outcomes.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.